CIK 0001393434
- Large accelerated filer
OCULAR THERAPEUTIX, INC
Sign in to watch- Ticker
- OCUL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 781-357-4000
- Business address
- 14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA, 01730
- Former names
- I-THERAPEUTIX INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $799,174
- in 9 filings, $788K under 10b5-1 plans
Net −$799,174. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dugel Pravin −$233K Reporting owner sold <1% of stake
- Saroj Namrata −$232K Chief Business Officer sold 14% of stake
- Heier Jeffrey S. −$112K Chief Scientific Officer sold 4% of stake
- Kaiser Peter −$103K Chief Development Officer sold 5% of stake
- Anderman Todd −$87K Chief Legal Officer sold 8% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-03-15 | Goldstein Michael H. Chief Medical Officer | Purchase | +10,000 | $4.15 | $42K | 13,686 |
| 2019-03-13 | LINDSTROM RICHARD L MD Director | Purchase | +56,441 | $4.33 | $244K | 100,000 |
| 2019-01-02 | Bollag Daniel M Sr. VP Reg. Affairs & Quality | Grant or award · Stock Option (Right to Buy) | +180,000 | 180,000 | ||
| 2019-01-02 | Hanley Kevin F. Sr. VP Technical Operations | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2019-01-02 | Sawhney Amarpreet Director | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2019-01-02 | Notman Donald Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2019-01-02 | Mattessich Antony C. President and CEO | Grant or award · Stock Option (Right to Buy) | +400,000 | 400,000 | ||
| 2019-01-02 | Goldstein Michael H. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2018-12-14 | Hanley Kevin F. | Purchase | +10,000 | $5.50 | $55K | 20,000 |
| 2018-12-10 | Hanley Kevin F. | Purchase | +10,000 | $5.60 | $56K | 10,000 |
| 2018-12-06 | Bollag Daniel M | Purchase | +17,400 | $5.76 | $100K | 42,100 |
| 2018-08-20 | Mattessich Antony C. President & CEO | Purchase | +20,000 | $5.95 | $119K | 57,900 |
| 2018-08-14 | Notman Donald Chief Financial Officer | Purchase | +12,500 | $6.29 | $79K | 17,300 |
| 2018-08-10 | Mattessich Antony C. President and CEO | Purchase | +16,900 | $6.23 | $105K | 37,900 |
| 2018-06-14 | Heier Jeffrey S. Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2018-06-14 | PEACOCK BRUCE Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2018-06-14 | Warden Charles M Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2018-06-14 | OSHEA WILLIAM J Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2018-06-14 | LINDSTROM RICHARD L MD Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2018-06-14 | Chadha Jaswinder Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 |
Page 18 of 27 · 522 trades